ArticleVeterinary dermatology2025
Effect of Gabapentin Administered With Prednisolone, Ciclosporin or a Placebo on Clinical Outcomes and Motor Activity in Cats With Atopic Skin Syndrome: A Prospective, Blinded, Placebo-Controlled Study.
Article in Veterinary dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGabapentin reportedly decreases central sensitisation, a disorder associated with chronic pruritus in humans, although this is not well documented in cats. Its combined use with the standard antipruritic therapy for feline atopic skin syndrome (FASS) is not yet described.
objectivesTo evaluate the impact of prednisolone, ciclosporin or placebo, with or without gabapentin, on lesional scores and actimetry in FASS cats. ANIMALS: Twenty-six cats from a laboratory colony with naturally acquired FASS. METHODS AND MATERIALS: Following a 12-week washout period, cats were allocated to one of three groups: prednisolone (1 mg/kg, n = 9), ciclosporin (7 mg/kg, n = 8) and placebo (Avicel, n = 9). Treatments were administered orally, once daily for 5 weeks (Week [W]0 to W4), then combined with gabapentin (10-15 mg/kg) for another 3 weeks. The Feline Dermatitis Extent and Severity Index (FeDESI) was assessed at baseline and W2, W4 and W7. Actimetry was recorded and analysed over weekend (WE) time points. A repeated-measures generalised mixed model was applied using the zero-inflated negative binomial (FeDESI) or log-normal (actimetry) distribution (α = 0.05).
resultsPrednisolone alone significantly improved FeDESI (p = 0.008), while ciclosporin required the addition of gabapentin to achieve a significant effect (p < 0.034). Gabapentin decreased FeDESI scores in all groups (p < 0.001) and demonstrated the highest incidence rate ratio (2.59) compared to placebo. Improvements in FeDESI were associated with significant (corresponding in intensity) decreases in motor activity. CONCLUSIONS AND CLINICAL RELEVANCE: Gabapentin, particularly when combined with prednisolone or ciclosporin, may reduce lesional score and actimetry-assessed itch in FASS cats, suggesting a potential central sensitisation in some cats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.